Drug Approval | April 26, 2022
USFDA approves first Covid-19 treatment for young children
This action makes Veklury the first approved Covid-19 treatment for children less than 12 years of age
This action makes Veklury the first approved Covid-19 treatment for children less than 12 years of age
A Promising Innovative Medicine (PIM) designation is an early indication that leniolisib is a candidate for the MHRA's Early Access to Medicines Scheme
In addition, common light chain antibodies generated by RenLite mice can greatly improve the efficiency of downstream assembly of complex drug molecules such as bispecific antibodies and bispecific antibody-drug conjugates (bsADCs)
It enables precise visualization and treatment access to the left heart
Designed to give instant insights on blood sugar, in-depth nutrition and wellness, this programme provides fitness assessments, personalisation and reports for doctors
Secretary, Department of Pharmaceuticals and Union Health Secretary Chair a Panel Discussion on the theme 'Indian Pharma Vision 2047'
The approval by the DCGI comes following recommendations by the Subject Expert Committee (SEC) on Covid-19 of the Central Drugs Standard Control Organisation(CDSCO)
The approval comes soon after Corbevax was given the nod for 12-15-year group
Covaxin was earlier approved for children 12-18 years of age
The two-dose regimen for ZyCoV-D was tested in 3100 healthy volunteers more than 12 years of age
Subscribe To Our Newsletter & Stay Updated
